Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-10-14

Clinical Trial Update: Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome [Phase 2]

View source ↗

Summary

Phase 2 efficacy and safety study of Aplindore in restless legs syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aplindore (aplindore)

Snippet

Sponsor: Neurogen Corporation | Conditions: Restless Legs Syndrome | Phase 2 | Status: TERMINATED